Abstract
Objective:
The aim of this study was to verify the influence of prostaglandin analogs and prostamide on central corneal thickness (CCT).
Methods:
A prospective analysis was done of CCT in glautomatous patients submitted to monotherapy with prostaglandin analogs (latanoprost 0.005% or travoprost 0.004%) or prostamide (bimatoprost 0.03%) during an 8-week period. A control group of patients without any ocular medication was also evaluated. CCT measurements were performed with a commercially available ultrasound pachymeter. A total of 73 patients were included in this study. Mean age was 68.5 ± 9.2 (range, 48–85) years old.
Results:
A statistically significant reduction in CCT was observed in all groups, except the control group (n = 21): Bimatoprost 0.03% group (n = 21): 544.41 ± 35.4 vs. 540.35 ± 35.9 μm (P = 0.039); travoprost 0.004% group (n = 17): 538.47 ± 32.0 vs. 532.25 ± 30.4 μm (P = 0.009); latanoprost 0.005% group (n = 14): 548.57 ± 32.4 vs. 543.88 ± 35.6 μm (P = 0.036).
Conclusion:
Topical therapy with prostaglandin analogs and bimatoprost is associated with CCT reduction over a period of at least 8 weeks.
Get full access to this article
View all access options for this article.